LAG-3 (Lymphocyte activation gene 3) protein is a checkpoint receptor that interacts with LSEC-tin, Galectin-3 and FGL1. This interaction leads to reduced production of IL-2 and IFN-γ. LAG-3 is widely expressed in different tumor types and modulates the tumor microenvironment through immunosuppressive effects. Differential expression in various tumor types influences patient prognosis, which is often associated with coexpression with immune checkpoint inhibitors, such as TIM-3, PD-1 and CTLA-4. Here, we discuss expression profiles in different tumor types. To date, many clinical trials have been conducted using LAG-3 inhibitors, which can be divided into anti-LAG-3 monoclonal antibodies, anti-LAG-3 bispecifics and soluble LAG-3-Ig fusion proteins. LAG-3 inhibitors supress T-cell proliferation and activation by disallowing for the interaction between LAG-3 to MHC-II. The process enhances anti-tumor immune response. In this paper, we will review the current state of knowledge on the structure, function and expression of LAG-3 in various types of cancer, as well as its correlation with overall prognosis, involvement in cell-based therapies and experimental medicine. We will consider the role of compounds targeting LAG-3 in clinical trials both as monotherapy and in combination, which will provide data relating to the efficacy and safety of proposed drug candidates.

Skin inflammatory and allergic conditions often result in symptoms such as erythema, edema, and pruritus, significantly impacting patients' quality of life. Traditional treatment approaches target either the inflammatory or allergic components individually, leaving the accompanying itch inadequately addressed. This study aims to explore the efficacy and safety of a combination therapy using diphenhydramine and lidocaine for managing inflammatory and allergic skin conditions with coexisting itch. Diphenhydramine, a first-generation antihistamine, exhibits potent antiallergic properties by inhibiting histamine receptors (H1). Lidocaine, a local anesthetic, possesses analgesic effects and alleviates pruritus by blocking sensory neurons and reducing capillary permeability. The synergistic effects of diphenhydramine and lidocaine hold promise in providing a comprehensive treatment option for individuals with inflammatory and allergic skin conditions. In this study, the efficacy and safety of combination therapy with diphenhydramine and lidocaine will be evaluated through its effects on symptom relief, inflammatory markers and patient satisfaction. Furthermore, we will analyze dermatoses where the combination therapy used had the best results. The study will also focus on market analysis and formulation availability. This investigation into the diphenhydramine and lidocaine combination therapy represents an innovative approach in dermatology, offering a unique solution for addressing both the underlying inflammation and the troublesome itch associated with inflammatory and allergic skin conditions.